Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy-associated renal dysfunction.

Literature DB >> 19564889

Chemotherapy-associated renal dysfunction.

Vaibhav Sahni¹, Devasmita Choudhury, Ziauddin Ahmed.

Abstract

The presence of renal dysfunction in a patient receiving chemotherapy can be devastating. Although many patients with cancer have underlying compromised renal function, some chemotherapeutic agents can actually induce renal abnormalities. An understanding of which traditional and newer chemotherapy agents can affect renal function is useful for physicians so that they can monitor patients for renal abnormalities and initiate preventive strategies to minimize renal complications. This Review highlights renal abnormalities associated with current chemotherapy agents and provides suggestions for preventive measures.

Entities: Disease Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2009 PMID： 19564889 DOI： 10.1038/nrneph.2009.97

Source DB: PubMed Journal: Nat Rev Nephrol ISSN： 1759-5061 Impact factor: 28.314

152 in total

1. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Authors: Tejas V Patel; Jeffrey A Morgan; George D Demetri; Suzanne George; Robert G Maki; Michael Quigley; Benjamin D Humphreys
Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506

Review 2. Pentostatin (Nipent): a review of potential toxicity and its management.

Authors: J Margolis; M R Grever
Journal: Semin Oncol Date: 2000-04 Impact factor: 4.929

3. Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin.

Authors: A M Albrecht; E Boldizsar; D J Hutchison
Journal: J Bacteriol Date: 1978-05 Impact factor: 3.490

4. The protective effect of melatonin on cisplatin nephrotoxicity.

Authors: G Sener; H Satiroglu; L Kabasakal; S Arbak; S Oner; F Ercan; M Keyer-Uysa
Journal: Fundam Clin Pharmacol Date: 2000 Nov-Dec Impact factor: 2.748

5. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544

Review 6. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors: Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal: Am J Kidney Dis Date: 2007-02 Impact factor: 8.860

7. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors: Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal: J Clin Oncol Date: 2008-04-21 Impact factor: 44.544

Review 8. Nephrotoxicity of semustine.

Authors: R B Weiss; J G Posada; R A Kramer; M R Boyd
Journal: Cancer Treat Rep Date: 1983-12

9. Lung cancer and renal insufficiency: prevalence and anticancer drug issues.

Authors: Vincent Launay-Vacher; Reza Etessami; Nicolas Janus; Jean-Philippe Spano; Isabelle Ray-Coquard; Stéphane Oudard; Joseph Gligorov; Xavier Pourrat; Philippe Beuzeboc; Gilbert Deray; Jean-François Morere
Journal: Lung Date: 2008-10-22 Impact factor: 2.584

10. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.

Authors: A S Guleria; J C Yang; S L Topalian; J S Weber; D R Parkinson; M P MacFarlane; R L White; S M Steinberg; D E White; J H Einhorn
Journal: J Clin Oncol Date: 1994-12 Impact factor: 44.544

39 in total

Review 1. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

Authors: Yeong-Hau H Lien; Li-Wen Lai
Journal: Nat Rev Nephrol Date: 2010-12-14 Impact factor: 28.314

2. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.

Authors: Kevin R Kelly; Nashat Gabrail; Steven Weitman; John Sarantopoulos; Anthony J Olszanski; William Edenfield; Jurgen Venitz; Guru Reddy; Allen Yang; Steven J Hasal; A Craig Lockhart
Journal: Cancer Chemother Pharmacol Date: 2016-09-16 Impact factor: 3.333

Chemotherapy-associated renal dysfunction.

1. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Review 2. Pentostatin (Nipent): a review of potential toxicity and its management.

3. Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin.

4. The protective effect of melatonin on cisplatin nephrotoxicity.

5. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Review 6. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

7. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Review 8. Nephrotoxicity of semustine.

9. Lung cancer and renal insufficiency: prevalence and anticancer drug issues.

10. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.

Review 1. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

2. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment.

Review 3. The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

4. Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity.

Review 5. Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

6. In Vitro and in Vivo Mechanism of Bone Tumor Inhibition by Selenium-Doped Bone Mineral Nanoparticles.

7. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.

Review 8. Emergence of biomarkers in nephropharmacology.

9. Emodin ameliorates cisplatin-induced apoptosis of rat renal tubular cells in vitro by activating autophagy.

Review 10. Graphene-based platforms for cancer therapeutics.